← 產業報告目錄

Enzyme, Peptide and MAB Therapeutics Market, By Product Type (Monoclonal Antibody, Peptide Therapeutics, and Enzyme Therapy), By Manufacturing Technology (Recombinant Technology, Protein Engineering, Hybridoma Technology, and Others), By Application (Cancer, Gaucher Disease, Fabry Disease, Pompe Disease, Acute Myocardial Infarction, Cystic Fibrosis, Gout, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

出版商 Coherent Market Insights出版日期 2026-07-29頁數 250報告編號 CMR-a10e9f2080

授權報價

Single User Price$4,500 USD
Site License Price$7,000 USD
Enterprisewide Price (Global Site License)$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global enzyme, peptide and MAB therapeutics market is estimated to be valued at USD 425,918.7 Mn in 2026 and is expected to reach USD 982,657.9 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2026 to 2033. The global enzyme, peptide, and MAB therapeutics market is a rapidly growing sector of the biopharmaceutical market owing to the increasing use of targeted therapeutics for treating chronic, rare, autoimmune, metabolic and oncological conditions. These biologic therapeutics offer high specificity, improved efficacy, and reduced off-target effects compared to conventional small-molecule drugs, making them integral to modern precision medicine. The global enzyme, peptide and MAB therapeutics market growth is being witnessed due to the continuous advancements in the recombinant DNA technology, protein engineering, and peptide synthesis which is coupled with increased research & development and manufacturing investments in the field of biologics. Rising number of regulatory approvals for biologic therapeutics, increasing pace in biosimilar development and application of artificial intelligence in the discovering of biologic drugs, and ever-growing demand for personalized and targeted drug molecules based on specific diseases are contributing toward market growth. Market Dynamics The global enzyme, peptide and MAB therapeutics market is driven by rising prevalence of chronic diseases, increasing adoption of precision medicine, and continuous advancements in biologics research. Growing investments in recombinant DNA technology, protein engineering, and peptide synthesis have accelerated the development of highly targeted therapies with improved efficacy and safety However, a number of constraints are present in the market, such as high development and manufacturing costs, complex biologics production processes, stringent regulatory requirements, and limited accessibility due to premium pricing. Nevertheless, ongoing innovation in biologics manufacturing, increasing adoption of biosimilars, advancements in AI-enabled drug discovery, and expanding healthcare access across emerging economies will offer new opportunities for growth in enzyme, peptide and MAB therapeutics market. Key Features of the Study • This report provides in-depth analysis of the global enzyme, peptide and MAB therapeutics market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global enzyme, peptide and MAB therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Eli Lilly and Company, AstraZeneca PLC, Novartis AG, Sanofi S.A., and Merck & Co., Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global enzyme, peptide and MAB therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global enzyme, peptide and MAB therapeutics market Market Segmentation • Product Type Insights (Revenue, USD Mn, 2021 - 2033) o Monoclonal Antibody o Peptide Therapeutics o Enzyme Therapy • Manufacturing Technology Insights (Revenue, USD Mn, 2021 - 2033) o Recombinant Technology o Protein Engineering o Hybridoma Technology o Others • Application Insights (Revenue, USD Mn, 2021 - 2033) o Cancer o Gaucher Disease o Fabry Disease o Pompe Disease o Acute Myocardial Infarction o Cystic Fibrosis o Gout o Others • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o F. Hoffmann-La Roche Ltd. o Amgen Inc. o AbbVie Inc. o Bristol-Myers Squibb Company o Johnson & Johnson o Eli Lilly and Company o AstraZeneca PLC o Novartis AG o Sanofi S.A. o Merck & Co., Inc.
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Enzyme, Peptide and MAB Therapeutics Market, By Product Type  Global Enzyme, Peptide and MAB Therapeutics Market, By Manufacturing Technology  Global Enzyme, Peptide and MAB Therapeutics Market, By Application  Global Enzyme, Peptide and MAB Therapeutics Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Industry Trends 4. Global Enzyme, Peptide and MAB Therapeutics Market, By Product Type, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Monoclonal Antibody  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Peptide Therapeutics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Enzyme Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 5. Global Enzyme, Peptide and MAB Therapeutics Market, By Manufacturing Technology, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Recombinant Technology  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Protein Engineering  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Hybridoma Technology  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Enzyme, Peptide and MAB Therapeutics Market, By Application, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Gaucher Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Fabry Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Pompe Disease  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Acute Myocardial Infarction  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Cystic Fibrosis  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Gout  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Enzyme, Peptide and MAB Therapeutics Market, By Region, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Manufacturing Technology, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Manufacturing Technology, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Manufacturing Technology, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Manufacturing Technology, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Manufacturing Technology, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Manufacturing Technology, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o F. Hoffmann-La Roche Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Amgen Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AbbVie Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Bristol-Myers Squibb Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Johnson & Johnson  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Eli Lilly and Company  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca PLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Sanofi S.A.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Merck & Co., Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Enzyme, Peptide and MAB Therapeutics Market' - Global forecast to 2033
圖表清單 List of Tables & Figures
NA NA

提及公司

o F. Hoffmann-La Roche Ltd.o Amgen Inc.o AbbVie Inc.o Bristol-Myers Squibb Companyo Johnson & Johnsono Eli Lilly and Companyo AstraZeneca PLCo Novartis AGo Sanofi S.A.o Merck & Co.Inc.

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們